Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 11.83 |
|---|---|
| High | 11.96 |
| Low | 11.32 |
| Bid | 11.32 |
| Offer | 12.00 |
| Previous close | 12.02 |
| Average volume | 673.44k |
|---|---|
| Shares outstanding | 31.29m |
| Free float | 30.45m |
| P/E (TTM) | -- |
| Market cap | 376.11m USD |
| EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of Mar 12 2026 20:00 BST.
More ▼
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
- LENZ Therapeutics to Present at Upcoming Investor Conferences
- LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
- LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
- LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
- LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
- LENZ Therapeutics to Present at Upcoming Investor Conferences
- LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
- LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
- LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
More ▼
